logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Parsaclisib for marginal zone lymphoma – relapsed or refractory

< Back

Parsaclisib for marginal zone lymphoma – relapsed or refractory

Drugs

Cancer and Palliative Care

June 2021


Marginal zone lymphoma (MZL) is a rare group of non-Hodgkin’s lymphomas that affect a type of immune cell called B-cells. These MZLs are called low-grade as they are slow-growing and might not always cause symptoms. Some broad symptoms of MZLs are unexplained weight loss, night sweats and fever, however patients are often diagnosed with MZL when they are undergoing tests to investigate something else. Treatment of MZL involves watching and waiting to see how the lymphoma progresses over time with treatment being initiated when the condition worsens (relapses). If the lymphoma persists despite treatment this is known as being refractory. There is currently an unmet need for improved safety of treatment options.
Parsaclisib is an oral selective inhibitor of a protein that can increase B-cell growth and survival, which is a problem in MZL. Parsaclisib is in clinical development for the treatment of patients with relapse or refractory MZL who have never received treatment with a Bruton’s tyrosine kinase (BTK) inhibitor or have been previously treated with this.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts